A Phase 1 interventional study of BTT-1023 and Placebo in Rheumatoid Arthritis, sponsored by Biotie Therapies Corp.. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Biotie Therapies Corp. · Phase 1, Interventional, and Treatment
Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 24 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Biotie Therapies Corp. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Drug: BTT-1023
Drug: Placebo
intravenous
Intravenous
Incidence and intensity of adverse events
Time frame: 17 wk
Serum concentrations of the verum
Time frame: 17 wk
Disease activity
Time frame: 17 wk
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biotie Therapies Corp.